Antengene Reports 46.7% Response Rate for ATG-022 in Phase II Gastric Cancer Trial
PUBT · 3d ago
Share
Listen to the news
- Antengene presented clinical results for ATG-022 and ATG-037 at the 2026 European Society for Medical Oncology congress.
- ATG-022 showed antitumor activity with a favorable safety profile in advanced gastric or gastroesophageal junction cancer, supporting advancement into pivotal Phase III testing.
- China's National Medical Products Administration cleared the Phase III trial to proceed.
- ATG-037 with pembrolizumab showed durable responses with a favorable safety profile in checkpoint inhibitor-resistant melanoma, supporting further evaluation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610252000PR_NEWS_USPR_____CN79628) on October 26, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending